Results 51 to 60 of about 5,240 (162)

Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency

Life Science Alliance
The NLRP3 inflammasome drives various diseases. Here, we describe novel potent and selective NLRP3-targeted inhibitors to bolster pharmacological studies and development of NLRP3-targeted therapies.
Lieselotte Vande Walle, Madhukar Said, Oonagh Paerewijck, Arinna Bertoni, Marco Gattorno, Bruno Linclau, Mohamed Lamkanfi   +6 more
doaj   +1 more source

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach

Clinical Epidemiology, 2018
John M Dennis,1 Beverley M Shields,2 Angus G Jones,2 Ewan R Pearson,3 Andrew T Hattersley,2 William E Henley1 On behalf of the MASTERMIND consortium 1Health Statistics Group, University of Exeter Medical School, Exeter, UK; 2National Institute for ...
Dennis JM, Shields BM, Jones AG, Pearson ER, Hattersley AT, Henley WE   +5 more
doaj  

The Development of Sulfonylurea Compounds

Hans Journal of Medicinal Chemistry, 2014
openaire   +1 more source

Discovery of novel quinazoline-sulfonamide derivatives with promising antidiabetic activity. [PDF]

Front Chem
Zayed MF, Muhammad Y, Alqurain AA, Banafa MAA, Omar AM.   +4 more
europepmc   +1 more source

Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Mickelson MM, McCoy RG.   +13 more
europepmc   +1 more source

Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

BMJ Open
Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH.   +7 more
europepmc   +1 more source

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. [PDF]

Drug Des Devel Ther
Aulifa DL, Wibisono TTDW, Ningsih JD, Christy GDAB, Pertiwi DS, Praja HM, Gazzali AM, Amaliah S, Budiman A.   +8 more
europepmc   +1 more source

Evaluation of %CV and average glucose derived from pre- and postprandial 6-point glucose measurements for assessing hypoglycemia risk. [PDF]

J Diabetes Investig
Soga R, Torimoto K, Uemura F, Okada Y, Nakayamada S.   +4 more
europepmc   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source